Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 382 entries
Sorted by: Best Match Show Resources per page
Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues.

Biomedical reports

Lin X, Liu YB, Hu H.
PMID: 28515909
Biomed Rep. 2017 May;6(5):495-502. doi: 10.3892/br.2017.890. Epub 2017 Apr 10.

The hepatokine fibroblast growth factor 21 (FGF21) is a novel polypeptide ligand, which is involved in glucose and lipid metabolism, and contributes significantly to lowering body weight and enhancing insulin sensitivity. A large number of pre-clinical and clinical results...

Cite
Lin X, Liu YB, Hu H. Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues. Biomed Rep. 2017;6(5):495-502doi: 10.3892/br.2017.890.
Lin, X., Liu, Y. B., & Hu, H. (2017). Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues. Biomedical reports, 6(5), 495-502. https://doi.org/10.3892/br.2017.890
Lin, Xiaolong, et al. "Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues." Biomedical reports vol. 6,5 (2017): 495-502. doi: https://doi.org/10.3892/br.2017.890
Lin X, Liu YB, Hu H. Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues. Biomed Rep. 2017 May;6(5):495-502. doi: 10.3892/br.2017.890. Epub 2017 Apr 10. PMID: 28515909; PMCID: PMC5431415.
Copy Download .nbib Format: NLM
Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.

Journal of diabetes investigation

Hui E, Xu A, Bo Yang H, Lam KS.
PMID: 24843689
J Diabetes Investig. 2013 Sep 13;4(5):413-25. doi: 10.1111/jdi.12093. Epub 2013 May 06.

Non-alcoholic fatty liver disease (NAFLD) describes a spectrum of liver conditions from simple steatosis, steatohepatitis to end-stage liver disease. The prevalence of NAFLD has been on the rise in many parts of the world, including Asia, and NAFLD is...

Cite
Hui E, Xu A, Bo Yang H, et al. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J Diabetes Investig. 2013;4(5):413-25doi: 10.1111/jdi.12093.
Hui, E., Xu, A., Bo Yang, H., & Lam, K. S. (2013). Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. Journal of diabetes investigation, 4(5), 413-25. https://doi.org/10.1111/jdi.12093
Hui, Elaine, et al. "Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines." Journal of diabetes investigation vol. 4,5 (2013): 413-25. doi: https://doi.org/10.1111/jdi.12093
Hui E, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J Diabetes Investig. 2013 Sep 13;4(5):413-25. doi: 10.1111/jdi.12093. Epub 2013 May 06. PMID: 24843689; PMCID: PMC4025109.
Copy Download .nbib Format: NLM
Fructose ingestion acutely stimulates circulating FGF21 levels in humans.

Molecular metabolism

Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E.
PMID: 25685689
Mol Metab. 2014 Oct 08;4(1):51-7. doi: 10.1016/j.molmet.2014.09.008. eCollection 2015 Jan.

OBJECTIVE: Fibroblast growth factor 21 (FGF21) is a hormone with pleiotropic metabolic activities which, in rodents, is robustly regulated by fasting and ketogenic diets. In contrast, similar dietary interventions have either no or minimal effects on circulating FGF21 in...

Cite
Dushay JR, Toschi E, Mitten EK, et al. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab. 2014;4(1):51-7doi: 10.1016/j.molmet.2014.09.008.
Dushay, J. R., Toschi, E., Mitten, E. K., Fisher, F. M., Herman, M. A., & Maratos-Flier, E. (2015). Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Molecular metabolism, 4(1), 51-7. https://doi.org/10.1016/j.molmet.2014.09.008
Dushay, Jody R, et al. "Fructose ingestion acutely stimulates circulating FGF21 levels in humans." Molecular metabolism vol. 4,1 (2015): 51-7. doi: https://doi.org/10.1016/j.molmet.2014.09.008
Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab. 2014 Oct 08;4(1):51-7. doi: 10.1016/j.molmet.2014.09.008. eCollection 2015 Jan. PMID: 25685689; PMCID: PMC4314524.
Copy Download .nbib Format: NLM
Laparoscopic gastric plication and its effect on saccharide and lipid metabolism: a 12-month prospective study.

Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques

Bužga M, Holéczy P, Švagera Z, Zonča P.
PMID: 26649086
Wideochir Inne Tech Maloinwazyjne. 2015 Sep;10(3):398-405. doi: 10.5114/wiitm.2015.54103. Epub 2015 Sep 14.

INTRODUCTION: Laparoscopic greater curvature plication (LGCP) is a novel restrictive technique that reduces gastric volume by plication of the greater curvature. The advantage of LGCP is its reversibility in comparison to laparoscopic sleeve gastrectomy. Nowadays, the long-term LGCP efficacy,...

Cite
Bužga M, Holéczy P, Švagera Z, et al. Laparoscopic gastric plication and its effect on saccharide and lipid metabolism: a 12-month prospective study. Wideochir Inne Tech Maloinwazyjne. 2015;10(3):398-405doi: 10.5114/wiitm.2015.54103.
Bužga, M., Holéczy, P., Švagera, Z., & Zonča, P. (2015). Laparoscopic gastric plication and its effect on saccharide and lipid metabolism: a 12-month prospective study. Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques, 10(3), 398-405. https://doi.org/10.5114/wiitm.2015.54103
Bužga, Marek, et al. "Laparoscopic gastric plication and its effect on saccharide and lipid metabolism: a 12-month prospective study." Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques vol. 10,3 (2015): 398-405. doi: https://doi.org/10.5114/wiitm.2015.54103
Bužga M, Holéczy P, Švagera Z, Zonča P. Laparoscopic gastric plication and its effect on saccharide and lipid metabolism: a 12-month prospective study. Wideochir Inne Tech Maloinwazyjne. 2015 Sep;10(3):398-405. doi: 10.5114/wiitm.2015.54103. Epub 2015 Sep 14. PMID: 26649086; PMCID: PMC4653266.
Copy Download .nbib Format: NLM
Practical prospects for boosting hepatic production of the "pro-longevity" hormone FGF21.

Hormone molecular biology and clinical investigation

McCarty MF.
PMID: 26741352
Horm Mol Biol Clin Investig. 2015 Dec 19;30(2). doi: 10.1515/hmbci-2015-0057.

Fibroblast growth factor-21 (FGF21), produced mainly in hepatocytes and adipocytes, promotes leanness, insulin sensitivity, and vascular health while down-regulating hepatic IGF-I production. Transgenic mice overexpressing FGF21 enjoy a marked increase in median and maximal longevity comparable to that evoked...

Cite
McCarty MF. Practical prospects for boosting hepatic production of the "pro-longevity" hormone FGF21. Horm Mol Biol Clin Investig. 2015;30(2)doi: 10.1515/hmbci-2015-0057.
McCarty, M. F. (2015). Practical prospects for boosting hepatic production of the "pro-longevity" hormone FGF21. Hormone molecular biology and clinical investigation, 30(2), . https://doi.org/10.1515/hmbci-2015-0057
McCarty, Mark F. "Practical prospects for boosting hepatic production of the "pro-longevity" hormone FGF21." Hormone molecular biology and clinical investigation vol. 30,2 (2015). doi: https://doi.org/10.1515/hmbci-2015-0057
McCarty MF. Practical prospects for boosting hepatic production of the "pro-longevity" hormone FGF21. Horm Mol Biol Clin Investig. 2015 Dec 19;30(2). doi: 10.1515/hmbci-2015-0057. PMID: 26741352.
Copy Download .nbib Format: NLM
Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.

Open heart

McCarty MF, DiNicolantonio JJ.
PMID: 25685364
Open Heart. 2015 Jan 29;2(1):e000205. doi: 10.1136/openhrt-2014-000205. eCollection 2015.

The α-glucosidase inhibitor acarbose, which slows carbohydrate digestion and blunts postprandial rises in plasma glucose, has long been used to treat patients with type 2 diabetes or glucose intolerance. Like metformin, acarbose tends to aid weight control, postpone onset...

Cite
McCarty MF, DiNicolantonio JJ. Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart. 2015;2(1):e000205doi: 10.1136/openhrt-2014-000205.
McCarty, M. F., & DiNicolantonio, J. J. (2015). Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open heart, 2(1), e000205. https://doi.org/10.1136/openhrt-2014-000205
McCarty, Mark F, and DiNicolantonio, James J. "Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1." Open heart vol. 2,1 (2015): e000205. doi: https://doi.org/10.1136/openhrt-2014-000205
McCarty MF, DiNicolantonio JJ. Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart. 2015 Jan 29;2(1):e000205. doi: 10.1136/openhrt-2014-000205. eCollection 2015. PMID: 25685364; PMCID: PMC4316590.
Copy Download .nbib Format: NLM
Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting.

Frontiers in endocrinology

Antonellis PJ, Hayes MP, Adams AC.
PMID: 27445980
Front Endocrinol (Lausanne). 2016 Jun 30;7:77. doi: 10.3389/fendo.2016.00077. eCollection 2016.

Fibroblast growth factor 21 (FGF21) is a pleotropic metabolic regulator, expression of which is elevated during fasting. To this end, the precise role played by FGF21 in the biology of fasting has been the subject of several recent studies,...

Cite
Antonellis PJ, Hayes MP, Adams AC. Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting. Front Endocrinol (Lausanne). 2016;7:77doi: 10.3389/fendo.2016.00077.
Antonellis, P. J., Hayes, M. P., & Adams, A. C. (2016). Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting. Frontiers in endocrinology, 777. https://doi.org/10.3389/fendo.2016.00077
Antonellis, Patrick Joseph, et al. "Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting." Frontiers in endocrinology vol. 7 (2016): 77. doi: https://doi.org/10.3389/fendo.2016.00077
Antonellis PJ, Hayes MP, Adams AC. Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting. Front Endocrinol (Lausanne). 2016 Jun 30;7:77. doi: 10.3389/fendo.2016.00077. eCollection 2016. PMID: 27445980; PMCID: PMC4928592.
Copy Download .nbib Format: NLM
Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk.

Diabetes & metabolism journal

Jin L, Lin Z, Xu A.
PMID: 26912152
Diabetes Metab J. 2016 Feb;40(1):22-31. doi: 10.4093/dmj.2016.40.1.22.

Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on energy metabolism and insulin sensitivity. Besides its antiobese and antidiabetic activity, FGF21 also possesses the protective effects against atherosclerosis. Circulating levels of FGF21 are elevated in...

Cite
Jin L, Lin Z, Xu A. Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. Diabetes Metab J. 2016;40(1):22-31doi: 10.4093/dmj.2016.40.1.22.
Jin, L., Lin, Z., & Xu, A. (2016). Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. Diabetes & metabolism journal, 40(1), 22-31. https://doi.org/10.4093/dmj.2016.40.1.22
Jin, Leigang, et al. "Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk." Diabetes & metabolism journal vol. 40,1 (2016): 22-31. doi: https://doi.org/10.4093/dmj.2016.40.1.22
Jin L, Lin Z, Xu A. Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. Diabetes Metab J. 2016 Feb;40(1):22-31. doi: 10.4093/dmj.2016.40.1.22. PMID: 26912152; PMCID: PMC4768047.
Copy Download .nbib Format: NLM
Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action.

Molecular metabolism

Ost M, Coleman V, Voigt A, van Schothorst EM, Keipert S, van der Stelt I, Ringel S, Graja A, Ambrosi T, Kipp AP, Jastroch M, Schulz TJ, Keijer J, Klaus S.
PMID: 26909316
Mol Metab. 2015 Nov 24;5(2):79-90. doi: 10.1016/j.molmet.2015.11.002. eCollection 2016 Feb.

OBJECTIVE: Fibroblast growth factor 21 (FGF21) was recently discovered as stress-induced myokine during mitochondrial disease and proposed as key metabolic mediator of the integrated stress response (ISR) presumably causing systemic metabolic improvements. Curiously, the precise cell-non-autonomous and cell-autonomous relevance...

Cite
Ost M, Coleman V, Voigt A, et al. Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Mol Metab. 2015;5(2):79-90doi: 10.1016/j.molmet.2015.11.002.
Ost, M., Coleman, V., Voigt, A., van Schothorst, E. M., Keipert, S., van der Stelt, I., Ringel, S., Graja, A., Ambrosi, T., Kipp, A. P., Jastroch, M., Schulz, T. J., Keijer, J., & Klaus, S. (2016). Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Molecular metabolism, 5(2), 79-90. https://doi.org/10.1016/j.molmet.2015.11.002
Ost, Mario, et al. "Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action." Molecular metabolism vol. 5,2 (2016): 79-90. doi: https://doi.org/10.1016/j.molmet.2015.11.002
Ost M, Coleman V, Voigt A, van Schothorst EM, Keipert S, van der Stelt I, Ringel S, Graja A, Ambrosi T, Kipp AP, Jastroch M, Schulz TJ, Keijer J, Klaus S. Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Mol Metab. 2015 Nov 24;5(2):79-90. doi: 10.1016/j.molmet.2015.11.002. eCollection 2016 Feb. PMID: 26909316; PMCID: PMC4735627.
Copy Download .nbib Format: NLM
Overfeeding Dairy Cattle During Late-Pregnancy Alters Hepatic PPARα-Regulated Pathways Including Hepatokines: Impact on Metabolism and Peripheral Insulin Sensitivity.

Gene regulation and systems biology

Khan MJ, Jacometo CB, Graugnard DE, Corrêa MN, Schmitt E, Cardoso F, Loor JJ.
PMID: 24737933
Gene Regul Syst Bio. 2014 Apr 03;8:97-111. doi: 10.4137/GRSB.S14116. eCollection 2014.

Hepatic metabolic gene networks were studied in dairy cattle fed control (CON, 1.34 Mcal/kg) or higher energy (overfed (OVE), 1.62 Mcal/kg) diets during the last 45 days of pregnancy. A total of 57 target genes encompassing PPARα-targets/co-regulators, hepatokines, growth...

Cite
Khan MJ, Jacometo CB, Graugnard DE, et al. Overfeeding Dairy Cattle During Late-Pregnancy Alters Hepatic PPARα-Regulated Pathways Including Hepatokines: Impact on Metabolism and Peripheral Insulin Sensitivity. Gene Regul Syst Bio. 2014;8:97-111doi: 10.4137/GRSB.S14116.
Khan, M. J., Jacometo, C. B., Graugnard, D. E., Corrêa, M. N., Schmitt, E., Cardoso, F., & Loor, J. J. (2014). Overfeeding Dairy Cattle During Late-Pregnancy Alters Hepatic PPARα-Regulated Pathways Including Hepatokines: Impact on Metabolism and Peripheral Insulin Sensitivity. Gene regulation and systems biology, 897-111. https://doi.org/10.4137/GRSB.S14116
Khan, M Jawad, et al. "Overfeeding Dairy Cattle During Late-Pregnancy Alters Hepatic PPARα-Regulated Pathways Including Hepatokines: Impact on Metabolism and Peripheral Insulin Sensitivity." Gene regulation and systems biology vol. 8 (2014): 97-111. doi: https://doi.org/10.4137/GRSB.S14116
Khan MJ, Jacometo CB, Graugnard DE, Corrêa MN, Schmitt E, Cardoso F, Loor JJ. Overfeeding Dairy Cattle During Late-Pregnancy Alters Hepatic PPARα-Regulated Pathways Including Hepatokines: Impact on Metabolism and Peripheral Insulin Sensitivity. Gene Regul Syst Bio. 2014 Apr 03;8:97-111. doi: 10.4137/GRSB.S14116. eCollection 2014. PMID: 24737933; PMCID: PMC3981572.
Copy Download .nbib Format: NLM
Erratum: Fibroblast growth factor 21 and fructose dynamics in humans.

Obesity science & practice

[No authors listed]
PMID: 30820333
Obes Sci Pract. 2019 Feb 19;5(1):91. doi: 10.1002/osp4.317. eCollection 2019 Feb.

[This corrects the article DOI: 10.1002/osp4.295.].

Cite
Erratum: Fibroblast growth factor 21 and fructose dynamics in humans. Obes Sci Pract. 2019;5(1):91doi: 10.1002/osp4.317.
(2019). Erratum: Fibroblast growth factor 21 and fructose dynamics in humans. Obesity science & practice, 5(1), 91. https://doi.org/10.1002/osp4.317
"Erratum: Fibroblast growth factor 21 and fructose dynamics in humans." Obesity science & practice vol. 5,1 (2019): 91. doi: https://doi.org/10.1002/osp4.317
Erratum: Fibroblast growth factor 21 and fructose dynamics in humans. Obes Sci Pract. 2019 Feb 19;5(1):91. doi: 10.1002/osp4.317. eCollection 2019 Feb. PMID: 30820333; PMCID: PMC6381307.
Copy Download .nbib Format: NLM
A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents.

Clinical and experimental gastroenterology

El Sagheer GM, Ahmad AK, Abd-ElFattah AS, Saad ZM, Hamdi L.
PMID: 30425548
Clin Exp Gastroenterol. 2018 Oct 24;11:415-422. doi: 10.2147/CEG.S173484. eCollection 2018.

BACKGROUND: Fibroblast growth factor (FGF) 21 was reported to be induced by different injurious agents, including chronic hepatitis C (CHC) virus, affecting the liver. The aims of this study were to evaluate the FGF21 levels in CHC patients before...

Cite
El Sagheer GM, Ahmad AK, Abd-ElFattah AS, et al. A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents. Clin Exp Gastroenterol. 2018;11:415-422doi: 10.2147/CEG.S173484.
El Sagheer, G. M., Ahmad, A. K., Abd-ElFattah, A. S., Saad, Z. M., & Hamdi, L. (2018). A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents. Clinical and experimental gastroenterology, 11415-422. https://doi.org/10.2147/CEG.S173484
El Sagheer, Ghada M, et al. "A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents." Clinical and experimental gastroenterology vol. 11 (2018): 415-422. doi: https://doi.org/10.2147/CEG.S173484
El Sagheer GM, Ahmad AK, Abd-ElFattah AS, Saad ZM, Hamdi L. A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents. Clin Exp Gastroenterol. 2018 Oct 24;11:415-422. doi: 10.2147/CEG.S173484. eCollection 2018. PMID: 30425548; PMCID: PMC6204854.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 382 entries